Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantginis raised the stock's price target to $20 from $9, citing confidence in the company's growth and financial health. The company maintains a solid cash position with over $300 million runway extending into mid-2028, supporting a clear path to profitability. Other analysts, including Goldman Sachs, also hold positive views, reinforcing strong market optimism for Iovance's future.
Iovance Biotherapeutics' recent analyst optimism follows its strong revenue growth outlook for 2026. For readers following the Health sector, here is Pluang's market snapshot as of Sep 30, 2026 02:41 WIB: out of 100 priced US Health stocks, 35 rose and 65 fell today. Notable movers include XRAY at USD 9.00 with a -3.02% change and a typical hold time of 71 days, AMPH at USD 26.64 with a -2.74% change and Pluang order activity of 64% Sell / 36% Buy, and ENVB at USD 1.43 with a -2.72% change and 70% Buy activity, held typically for 13 days.
Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...
First Financial Bank, a subsidiary of First Financial Bankshares, Inc., announced it will open a new full-service branch in Bee Cave, Texas, in late October. This marks the bank's 81st location and strengthens its presence in Central Texas and the gr...
Republic Services, a leading environmental services company, will announce its third quarter 2026 financial results after market close on October 29, 2026. The company will host a live investor conference call at 5 p.m. Eastern Time the same day, acc...
The SPDR Gold Trust (GLD) ETF sells a small portion of its gold holdings every month to pay its 0.40% annual expenses, as it holds no cash or income. This sale reduces the gold backing each share over time and is treated by the IRS as if the investor...
Precision Optics Corporation reported a strong Q4 with record revenue of $8.8 million, a 42% increase year-over-year, surpassing analyst estimates of $7.1 million. The company also beat EPS expectations, posting -$0.01 versus the predicted -$0.06, si...
